Disease subsets in clinical practice

Scleroderma: From Pathogenesis to Comprehensive Management

Volumn , Issue , 2012, Pages 45-52

  Domsic, Robyn T ^a   Medsger, Thomas A ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Autoantibodies; Classification criteria; Clinical practice; Disease subsets; Patient profiles; Subset classification; Systemic sclerosis

Indexed keywords

EID: 84871651720     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-5774-0_6     Document Type: Chapter

References (35)

1. Fries JF, Hochberg M, Medsger Jr TA, et al. Criteria for rheumatic disease: different types and different functions. Arthritis Rheum. 1994;37:454-62.
2. Masi AT, Rodnan GP, Medsger Jr TA, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581-90.
3. Vayssairat M, Baudot N, Abuaf N. Long-term follow-up study of 184 patients with definite systemic sclerosis: classification considerations. Clin Rheumatol. 1992;11:356-63.
4. Scussel-Lonzetti LS, Joyal F, Raynaud J-P, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum. 2001;44:735-6.
5. LeRoy EC, Medsger Jr TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-6.
6. Matucci-Cerinic M, Allanore Y, Czirjek L, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis. 2009;68(9):1377-80.
7. Tan EM, Cohen AS, Fries JR, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;24:1271-7.
8. Bohan A, Peter JB, Bowman RL, et al. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977;56:255-86.
9. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-5.
10. Poormoghim H, Lucas M, Fertig N, Medsger Jr TA. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000;43:444-51.
11. Masi AT. Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups I nearly disease to outcome and serologic reactivity. J Rheumatol. 1988;15:894-8.
12. Giordano M, Valentini C, Migliaresi S, et al. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 1986;13:911-6.
13. Steen VD, Medsger Jr TA. Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am. 1990;16:1-10.
14. Brennan P, Silman A, Black C, et al. Reliability of skin involvement measures in scleroderma. Br J Rheumatol. 1992;31:460-7.
15. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281-5.
16. Rodnan GP, Lipinski E, Lucksick J. Skin thickness and collagen content in progressive systemic sclerosis (scleroderma) and localized scleroderma. Arthritis Rheum. 1979;22:130-40.
17. Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Fghali-Bostwick C. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63:783-94.
18. Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger Jr TA. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis. 2011;70:104-9.
19. Domsic RT, Lucas M, Medsger TA. Internal organs are affected very early in diffuse scleroderma: implications for clinical trials (abstract). Clin Exp Rheum Scleroderma Care Res. 2010;62(28 Suppl):S-63.
20. Silver RM, Medsger TA, Bolster MB. Systemic sclerosis and scleroderma variants: clinical aspects. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1633-80.
21. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis. Arthritis Rheum. 1999;42:1194-203.
22. Rashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-66.
23. Khanna D, Clements PJ, Furst DE, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement:a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60:1102-11.
24. Medsger Jr TA. Classification, prognosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 17-8.
25. Steen VD, Medsger Jr TA. Skin flares in systemic sclerosis with diffuse scleroderma (dcSSc). Arthritis Rheum. 2000;43:S319.
26. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 1986;13:911-6.
27. Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am. 1998;27:563-94.
28. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger Jr TA. A comparison between anti-Th/To and anti-centromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum. 2003;48:203-9.
29. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35:35-42.
30. Oddis CV, Eisenbeis Jr CH, Reidbord HE, Steen VD, Medsger Jr TA. Vasculitis in systemic sclerosis: a subset of patients with the CREST variant, Sjögren's syndrome and neurologic complications. J Rheumatol. 1987;14:942-8.
31. Fregeau DR, Leung PS, Coppel RL, McNeilage J, Medsger Jr TA, Gershwin ME. Autoantibodies to mitochondria in systemic sclerosis. Arthritis Rheum. 1988;31:386-92.
32. Gordon MB, Klein I, Dekker A, Rodnan GP, Medsger Jr TA. Thyroid disease i progressive systemic sclerosis: increased frequency of glandular fibrosis and hypothyroidism. Ann Intern Med. 1981;95:431-5.
33. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580-8.
34. Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger Jr TA. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum. 2005;52:2425-32.
35. Perera A, Fertig N, Lucas M, Medsger Jr TA. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum. 2007;56:2740-6.